Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma

Inclusion Criteria: * Voluntary written informed consent; * Age ≥18 years old, ≤75 years old, male and female; * Expected survival ≥3 months; * The Eastern Cooperative Oncology Group (ECOG) physical fitness score was 0-2; * Ebv-positive nasopharyngeal carcinoma was diagnosed by in situ hybridization with Ebers (Eber-fish) . * Pathological Paraffin section testing (within 5 years before signing the informed consent form) ; * At least one measurable lesion according to RECIST v1.1 criteria for solid tumors; * Recurrent/metastatic nasopharyngeal carcinoma patients who had previously failed second-line or more systemic therapy; * An apheresis or venous access can be established and there are no other contraindications to blood cell isolation； * CTCAE 5.0 was lower than grade 1 in the side effects of previous anti-tumor therapy (radiotherapy, chemotherapy, targeted therapy, etc.) * During the study period and up to 6 months after the end of the administration, fertile subjects -LRB-both male and female) were required to use effective medical contraception. For women of reproductive age, a pregnancy test should be performed within 72 hours before the first dose, and the results were negative. Exclusion Criteria: * Active central nervous system metastases (except those that are stable after treatment)； * HIV positive, HBsAg positive and HBV DNA copy number positive (quantitative detection ≥1000 CPS/ml) , HCV antibody positive and HCV RNA positive; * Patients with mental or psychological disorders who can not cooperate with the treatment and evaluation of the curative effect; * Subjects with severe autoimmune disease and long-term use of immunosuppressants; * Active or uncontrolled infection requiring systemic therapy was present within 14 days prior to enrollment； * Any unstable systemic disease; * Complicated with dysfunction of important organs such as lung, brain and kidney. * Subjects had undergone major surgery or severe trauma within 4 weeks before receiving cell therapy, or were expected to undergo major surgery during the study period. * Participants received their last dose of radiation or anti-tumor therapy within 4 weeks of receiving the cell therapy. * Participants had or had had other cancers that were incurable for up to 3 years, except for cervical cancer in situ or skin basal-cell carcinoma, and other cancers that had disease-free survival of more than 5 years. * Treated with Chimeric antigen receptor t-cell therapy within six months. * Graft-versus-host disease (GVHD)； * Subjects who were receiving systemic steroid therapy before screening and who required long-term systemic steroid therapy during treatment as determined by the investigator (with the exception of inhaled or topical use) ; And subjects treated with systemic steroids within 72 hours before cell reinfusion (except for inhalation or topical use) . * Severe allergies or a history of allergies; * Subjects requiring anticoagulant therapy; * Pregnant or lactating women, or a six-month pregnancy plan (for both men and women)； * Researchers believe there are other reasons not to include people in treatment.